Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Schippinger, W; Regitnig, P; Bauernhofer, T; Ploner, F; Hofmann, G; Krippl, P; Wehrschütz, M; Lax, S; Carney, W; Neumann, R; Wernecke, KD; Samonigg, H.
The course of serum HER-2/neu levels as an independent prognostic factor for survival in metastatic breast cancer.
ONCOL REP. 2004; 11(6): 1331-1336.
Doi: 10.3892/or.11.6.1331
Web of Science
PubMed
FullText
FullText_MUG
Google Scholar
- Leading authors Med Uni Graz
- Schippinger Walter
- Co-authors Med Uni Graz
- Bauernhofer Thomas
- Hofmann Guenter
- Krippl Peter
- Ploner Ferdinand
- Regitnig Peter
- Samonigg Hellmut
- Wehrschütz Martin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The purpose of this study was to determine the impact of serum HER-2/neu level dynamics during the course of disease and treatment on the prognosis of patients with metastatic breast cancer. Two thousand and thirty-eight serum samples collected sequentially after disease relapse in 286 patients with metastatic breast cancer were measured by Bayer Immuno 1 trade mark assay retrospectively for serum HER-2/neu (cut-off level 15 ng/ml). One hundred and five patients (37%) presented with serum HER-2/neu continuously
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Aged, 80 and over -
- Antineoplastic Agents - therapeutic use
- Breast Neoplasms - blood
- Disease Progression - blood
- Enzyme-Linked Immunosorbent Assay - blood
- Female - blood
- Gene Amplification - blood
- Humans - blood
- Immunoenzyme Techniques - blood
- In Situ Hybridization, Fluorescence - blood
- Middle Aged - blood
- Neoplasm Recurrence, Local - blood
- Prognosis - blood
- Receptor, erbB-2 - blood
- Retrospective Studies - blood
- Survival Rate - blood
- Tumor Markers, Biological - analysis
- Find related publications in this database (Keywords)
- breast cancer
- serum HER-2/neu
- prognostic factors